Martin Shkreli, chief executive of Turing Pharmaceuticals and KaloBios Pharmaceuticals Inc. kbio, has been arrested on securities fraud charges, according to news reports Thursday. Prosecutors are charging Shkreli for illegally taking stock from biotech firm Retrophin Inc., which he founded, and using it to pay off unrelated business debts, Bloomberg reported. Reuters reported it witnessed Shkreli's arrest. Shkreli's arrest also stems from his time as manager of hedge fund MSMB Capital Management, the reports said. Shkreli recently faced a firestorm of criticism for Turing's decision to dramatically push up the price of anti-parasitic drug Daraprim to $750 a pill from $13.50 each.